FH and hereditary leiomyomatosis and renal cell cancer: Overall, we have defined a previously unidentified oncogenic event occuring in FH-deficient tumors, which study will be instrumental for understanding the mechanisms of tumorigenesis in HLRCC and the development of targeted treatments.